Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Mar 3, 2009

Premium

Mort Minaee has joined 454 Life Sciences as head of regulatory affairs. He will be responsible for the regulatory approval process as the company prepares for the diagnostic use of the 454 sequencing technology.

Minaee comes to 454 from Abbott Molecular Diagnostics, where he was director of regulatory and clinical affairs. At Abbott, he worked with Roche and Genentech on a companion diagnostic for the cancer drug Tarceva. In the past, he held a position with Siemens Medical Solutions, where he obtained approvals for software-based diagnostic devices.


Illumina CEO Jay Flatley has joined the board of directors Helixis, a Carlsbad, Calif.-based developer of nucleic acid analysis tools. Prior to coming to Illumina, Flatley was president and CEO of Molecular Dynamics, now part of GE Healthcare, and led that company's initial public offering in 1993.


Mari Baker has left her post as CEO of Navigenics to take the chief executive position at video game company PlayFirst. She will have "ongoing board roles" at Navigenics and Cozi Group, according to PlayFirst.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.